Literature DB >> 6310058

The spatio-temporal pattern of the axonopathy associated with the neurotoxicity of 3,4-dimethyl-2,5-hexanedione in the rat.

D C Anthony, F Giangaspero, D G Graham.   

Abstract

The neurotoxicity of the gamma-diketone 3,4-dimethyl-2,5-hexanedione(DMHD) was studied to determine the distribution of the neuropathologic changes and the temporal sequence during the intoxication period and following five and 15 weeks of recovery. Intoxication with 3,4-dimethyl-2,5-hexanedione at a daily dose of 0.25 mmoles/kg led to a profound clinical neuropathy, resulting in paralysis of all four limbs after 12-15 days. The cumulative toxic dose for this gamma-diketone was 3-4 mmoles/kg, indicating that dimethyl substitution increased the neurotoxicity of gamma-diketones by a factor of 20-30. The neuropathy was characterized histologically by giant axonal swellings in the proximal axon of the lower motor neuron in a distribution similar to IDPN (beta,beta'-iminodipropionitrile)-neuropathy, with swellings in the anterior horn, intraspinal anterior root, and the proximal anterior root. These swellings developed from six to 12 days of intoxication and were still evident after 15 weeks of recovery. The fact that dimethyl substitution of 2,5-hexanedione accelerated the neuropathy and was characterized by proximal axonal swellings has two important implications: 1) that formation of pyrrole derivatives may be an important step in the pathogenesis of gamma-diketone neuropathies, and 2) that the neurofilament neuropathies may represent a continuum of toxic neuropathies in which the rate of action of the neurotoxin ultimately determines the proximo-distal location of the axonal swellings.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310058     DOI: 10.1097/00005072-198309000-00007

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

1.  Monocyclic and dicyclic hydrocarbons: structural requirements for proximal giant axonopathy.

Authors:  Desire D Tshala-Katumbay; Valerie S Palmer; Michael R Lasarev; Robert J Kayton; Mohammad I Sabri; Peter S Spencer
Journal:  Acta Neuropathol       Date:  2006-07-28       Impact factor: 17.088

2.  Giant axon formation in mice lacking Kell, XK, or Kell and XK: animal models of McLeod neuroacanthocytosis syndrome.

Authors:  Xiang Zhu; Eun-Sook Cho; Quan Sha; Jianbin Peng; Yelena Oksov; Siok Yuen Kam; Mengfatt Ho; Ruth H Walker; Soohee Lee
Journal:  Am J Pathol       Date:  2014-01-07       Impact factor: 4.307

3.  Impaired expression of neuronal nitric oxide synthase in the gracile nucleus is involved in neuropathic changes in Zucker Diabetic Fatty rats with and without 2,5-hexanedione intoxication.

Authors:  Sheng-Xing Ma; Richard G Peterson; Edward M Magee; Paul Lee; Wai-Nang Paul Lee; Xi-Yan Li
Journal:  Neurosci Res       Date:  2015-10-28       Impact factor: 3.304

Review 4.  Neuroprotein Targets of γ-Diketone Metabolites of Aliphatic and Aromatic Solvents That Induce Central-Peripheral Axonopathy.

Authors:  Peter S Spencer
Journal:  Toxicol Pathol       Date:  2020-03-12       Impact factor: 1.902

5.  Neurofilaments are nonessential to the pathogenesis of toxicant-induced axonal degeneration.

Authors:  J D Stone; A P Peterson; J Eyer; T G Oblak; D W Sickles
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

6.  In vitro evidence that covalent crosslinking of neurofilaments occurs in gamma-diketone neuropathy.

Authors:  D G Graham; G Szakál-Quin; J W Priest; D C Anthony
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

Review 7.  The Role of Protein Adduction in Toxic Neuropathies of Exogenous and Endogenous Origin.

Authors:  Peter S Spencer; Xiao Chen
Journal:  Toxics       Date:  2021-04-29

8.  Axonopathy-inducing 1,2-diacetylbenzene forms adducts with motor and cytoskeletal proteins required for axonal transport.

Authors:  Mohammad I Sabri; Seyed B Hashemi; Michael R Lasarev; Peter S Spencer
Journal:  Neurochem Res       Date:  2007-06-19       Impact factor: 4.414

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.